COMMUNIQUÉS West-GlobeNewswire

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
07/05/2024
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
07/05/2024
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE [...]
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
07/05/2024
AI-informed drug design enabled approval to dose within one year of project initiation Data highlight use of AI to engineer investigative allele selective antisense oligonucleotide treatment for baby with ultra-rare [...]
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
07/05/2024
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR [...]
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
07/05/2024
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® [...]
Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO
07/05/2024
LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the [...]
Amolyt Pharma dévoile les abstracts acceptés pour présentation aux congrès de la GRS, de l'ECE et de l'ENDO
07/05/2024
LYON, France et CAMBRIDGE, Mass., 07 mai 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, société spécialisée dans le développement de peptides thérapeutiques ciblant les maladies endocriniennes et métaboliques rares, a annoncé [...]
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
07/05/2024
Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, [...]
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
07/05/2024
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to [...]
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
07/05/2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a [...]
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
07/05/2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused [...]
Reflect Scientific Inc. Announces Second Quarter Sale of Groundbreaking Aerospace Manufacturing Solution
07/05/2024
OREM, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leading provider of innovative cooling solutions, today announced sales of $105,000 attributable to the successful launch of the [...]
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
07/05/2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
07/05/2024
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference [...]
4DMT to Participate in Upcoming Investor Conference
07/05/2024
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic [...]
Cogent Biosciences Reports First Quarter 2024 Financial Results
07/05/2024
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations [...]
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
07/05/2024
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the [...]
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
07/05/2024
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance [...]
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
07/05/2024
Eterna reports the development of an mRNA-engineered iPSC line developed using UltraSlice™ to express a B2M-HLA-E fusion transgene in lieu of the endogenous B2M gene product to mimic native B2M expression The cells may [...]

Pages